LONDON: Directa Plus (AIM: DCTA), renowned for its graphene nanoplatelets products, is embarking on a fundraising venture to secure a minimum of £6.8 million and up to £6.9 million. The initiative involves a conditional placing and subscription, aiming to issue up to 38,361,106 new ordinary shares at 18p each. The company’s largest shareholder, Nant Capital,…